Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 5 (3), 125-9

Which Botanicals or Other Unconventional Anticancer Agents Should We Take to Clinical Trial?

Affiliations
Review

Which Botanicals or Other Unconventional Anticancer Agents Should We Take to Clinical Trial?

Andrew J Vickers. J Soc Integr Oncol.

Abstract

There is significant public and scientific interest as regards unconventional anticancer agents (complementary and alternative medicine [CAM] agents). This article describes five principles pertaining to the question of which CAM agents should be taken to clinical trial: (1) many CAM agents have been proposed as cancer treatments, far more than could possibly be studied in clinical trials; (2) claims by patients or practitioners are generally unhelpful in choosing which CAM agents to test; (3) laboratory studies can help determine which CAM agents to take to trial and with which cointerventions; (4) preliminary laboratory studies are essential to confirm safety before trials can be considered; and (5) the vast majority of anticancer CAM agents will be ineffective; our aim should be to discard agents from consideration as rapidly as possible.

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

MeSH terms

Substances

LinkOut - more resources

Feedback